openPR Logo
Press release

Investigation announced for Long-Term Investors in Provention Bio, Inc. (NASDAQ: PRVB) shares

09-15-2021 08:11 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Provention Bio, Inc. (NASDAQ: PRVB) shares.

An investigation on behalf of current long term investors in Provention Bio, Inc. (NASDAQ: PRVB) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Provention Bio, Inc..

Investors who are current long term investors in Provention Bio, Inc. (NASDAQ: PRVB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: PRVB stocks follows a lawsuit filed against Provention Bio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: PRVB stocks, concerns whether certain Provention Bio, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that the teplizumab BLA was deficient in its submitted form and would require additional data to secure FDA approval, that accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed, that the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Provention Bio, Inc. (NASDAQ: PRVB) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Provention Bio, Inc. (NASDAQ: PRVB) shares here

News-ID: 2394820 • Views: 506

More Releases from Shareholders Foundation

Investigation announced for Investors in NASDAQ: ABSI shares over possible Wrong …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Absci Corporation. Investors who purchased shares of Absci Corporation (NASDAQ: ABSI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Absci Corporation directors breached their fiduciary duties and caused damage to the company and its shareholders. Vancouver, WA based Absci
Investigation announced for Investors in shares of Revance Therapeutics, Inc. (N …
An investigation was announced over potential securities laws violations by Revance Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Revance Therapeutics, Inc. regarding its business, its prospects and its operations were
Investigation announced for Long-Term Investors in shares of Annovis Bio, Inc. ( …
An investigation was announced over possible breaches of fiduciary duties by certain directors and officers of Annovis Bio, Inc.. Investors who are current long term investors in Annovis Bio, Inc. (NYSE: ANVS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: ANVS stocks follows a lawsuit filed against Annovis
Investigation announced for Investors in shares of Reconnaissance Energy Africa …
An investigation was announced over potential securities laws violations by Reconnaissance Energy Africa Ltd. in connection with certain financial statements was announced. Investors who purchased shares of Reconnaissance Energy Africa Ltd. (OTC: RECAF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Reconnaissance Energy Africa Ltd. regarding its business, its

All 5 Releases


More Releases for Provention

PolTREG has presented an innovative method for the treatment of type 1 diabetes …
Researchers from the Polish Consortium PolTREG and STRATEGMED TREGS presented the initial results of phase II trial assessing regulatory T cells (Tregs) during the 80th Conference of the American Diabetes Association (ADA). The Polish company operates in the same area as the American company Provention Bio, which has presented a method for the treatment of presymptomatic patients with type 1 diabetes mellitus (T1DM) during the same event. The American company’s
Thelansis "Crohn’s disease (CD) – Market Outlook and Competitive Landscape r …
Report Snapshot:  Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two